Vepalimomab

Vepalimomab is an experimental mouse monoclonal antibody intended for the treatment of inflammations. It blocks vascular adhesion protein 1.[1] Development of the drug was discontinued in 2002.[2]

Vepalimomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetVAP-1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

References

  1. Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T (June 2005). "Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis". Basic & Clinical Pharmacology & Toxicology. 96 (6): 429–35. doi:10.1111/j.1742-7843.2005.pto_05.x. PMID 15910406.
  2. "Vepalimomab". AdisInsight. Springer Nature Switzerland AG.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.